Cargando…

Chinese ICU physicians’ knowledge of antibiotic pharmacokinetics/pharmacodynamics (PK/PD): a cross-sectional survey

BACKGROUND: Patients with sepsis have a high mortality rate, accumulated evidences suggest that an optimal antibiotic administration strategy based on pharmacokinetics/pharmacodynamics (PK/PD) can improve the prognosis of septic patients. Therefore, we assessed Chinese intensive care unit (ICU) phys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Wenchao, Lu, Difan, Zhou, Jia, Zhen, Junhai, Yan, Jing, Li, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920424/ https://www.ncbi.nlm.nih.gov/pubmed/35287666 http://dx.doi.org/10.1186/s12909-022-03234-9

Ejemplares similares

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients
por: Morrisette, Taylor, et al.
Publicado: (2019)

Integrated pharmacokinetic–Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets
por: Zeng, Qing Lin, et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model
por: Zhao, Yongda, et al.
Publicado: (2018)

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)
por: Custodio, Joseph, et al.
Publicado: (2017)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Profiles of Tulathromycin in an Experimental Intraperitoneal Haemophilus parasuis Infection Model in Neutropenic Guinea Pigs
por: Guo, Li-li, et al.
Publicado: (2021)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK(2)-PD) relationship of tacrolimus in liver transplant recipients
por: Tron, Camille, et al.
Publicado: (2020)

1560. Pharmacokinetics–Pharmacodynamics (PK-PD) of Gepotidacin (GEP) Against Escherichia coli in Murine Pyelonephritis and Thigh Infection Models
por: Barth, Aline, et al.
Publicado: (2019)

Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
por: Weng, Yan, et al.
Publicado: (2015)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)
por: Lepak, Alexander J, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli
por: Jitaree, Kamonchanok, et al.
Publicado: (2019)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets
por: Wang, Rui-Ling, et al.
Publicado: (2022)

Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine Streptococcus suis infection
por: Luo, Wanhe, et al.
Publicado: (2021)

1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropenic Thigh Model
por: Zhao, Miao, et al.
Publicado: (2018)

Assessing circadian rhythms in propofol PK and PD during prolonged infusion in ICU patients
por: Bienert, Agnieszka, et al.
Publicado: (2010)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Editorial: Antibiotics Special Issue on Pharmacokinetic/Pharmacodynamic Models of Antibiotics
por: Kebriaei, Razieh, et al.
Publicado: (2022)

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
por: Yoneyama, Tomoki, et al.
Publicado: (2020)

In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
por: Sun, Jian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8nvqd13e19r9g9flrnds539fv0